Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in TWIN Pregnancy Management

Overview

About this study

The primary objective of the study is to assess the clinical utility of combining noninvasive prenatal testing (NIPT)-based zygosity measurements with ultrasound chorionicity assessments for the management of twin pregnancies, as measured by the following endpoints: the overall frequency of NIPT-determined zygosity and monozygosity among twin pregnancies, the frequency of NIPT-determined zygosity rate among monochorionic and dichorionic twin pregnancies, and the proportion of twin pregnancies with twin-twin transfusion syndrome (TTTS) that are diagnosed late as compared with historical rates.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Female patients age 18 at the time of signing informed consent, up to 55 years of age.
Ultrasound confirmation of twin pregnancy no later than 20 weeks gestational age (GA), and prior to Panorama.
Panorama planned no later than 20 weeks GA.
Willing and able to provide written informed consent.
Willing and able to comply with institution’s standard of care prenatal procedures, including ultrasound assessments and Panorama.
- Note: subjects with known major congenital anomalies, known unbalanced chromosomal complement or ruptured membranes, may be enrolled in the study.

Exclusion Criteria:

Singleton or non-twin multiple pregnancy.
Ultrasound confirmation of twin pregnancy at 20 weeks 1 day GA or later.
Patient has received a Panorama test and the enrolling physician has received the Panorama test results prior to any ultrasound assessment of chorionicity & amnionicity.
Panorama testing is planned at 20 weeks 1 day GA or later.
Any confounding complication or condition that, in the opinion of the investigators, precludes participation in the study, such as evidence of TTTS or other monochorionic pregnancy complication already at the time of enrollment.
Unwilling or unable to participate in the institution’s standard of care prenatal ultrasound and/or testing with Panorama.
Unwilling or unable to provide written informed consent.

Eligibility last updated 4/26/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Myra Wick, M.D., Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Myra Wick, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials